Pfizer, Moderna strike deals with Canadian govt to secure millions of COVID-19 vaccine doses
Millions of doses will be supplied by both firms, while the vaccines are still in development and negotiations continue with other suppliers.
Canada announced Wednesday it has signed two agreements with American pharmaceutical firms Pfizer and Moderna for the delivery of COVID-19 vaccines in 2021.
Millions of doses will be supplied, but the vaccines are still in development while negotiations continue with other potential suppliers, Procurement Minister Anita Anand told a news conference.
They will also still need to obtain Health Canada regulatory approvals before being distributed to Canadians, she said.
The agreement with the American giant Pfizer concerns a vaccine candidate developed in partnership with Germany's BioNTech.
BioNTech and Pfizer reported the first conclusive trials of the BNT162 mRNA-based vaccine candidate in early July, after testing 45 people. They started large-scale clinical trials at the end of July, with 30,000 volunteers aged 18 to 35.
Moderna is to provide its mRNA-1273 vaccine candidate, which has started to be tested in thousands of Phase 3 clinical trial human participants.
On Tuesday, Canada's chief public health officer, Theresa Tam, warned that a vaccine will be a "very important aspect of the response," but will not bring a swift end to the coronavirus outbreak.
"We're planning, as a public health community, that we're going to have to manage this pandemic certainly over the next year, but certainly it may be planning for the longer term on the next two to three years during which the vaccine may play a role. But we don't know yet," Tam said.
"People might think that if we get a vaccine then everything goes back to normal the way it was before. That's not the case," added her deputy, Howard Njoo.
Canada had more than 118,000 cases of coronavirus and 8,996 patients have died, as of Wednesday.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
Dr Balram Bhargava, Director-General of ICMR said, "There are three things for a vaccine--(i) the safety, (ii) immunogenicity, and (iii) the efficacy."
Rich nations with 13% of world's population secure over half COVID-19 vaccine in late-stage trials, says Oxfam report
At least, 51% of 5.9 billion doses expected to be available for supply post successful trials have been snapped up by the US, Britian, Australia, Japan, Switzerland, Israel, the EU and Hong Kong and Macau, the report claimed
Bharat Bio's COVAXIN: Ten takeaways from successful animal trials of the experimental COVID-19 vaccine
The animal trials demonstrate that COVAXIN protected against SARS-CoV-2, and amped up two kinds of antibodies needed for a strong immune response against the virus.